1-5 of 5
Allison J Kaeding
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)

Susan Bal, Larry D Anderson, Jr., Omar Nadeem, Jesús G. Berdeja, Adriana Rossi, Tara Gregory, Mehmet Hakan Koçoğlu, Thomas G Martin, Daniel N. Egan, Luciano J. Costa, Hongxiang Hu, Jinjie Chen, Chaoqun Mei, Naomey Sarkis, Alok Shrestha, Safiyyah Ziyad, Wei-Ming Kao, Allison J Kaeding, Michael R. Burgess, Myo Htut
Journal: Blood
Blood (2024) 144 (Supplement 1): 922.
https://doi.org/10.1182/blood-2024-201356
Published: 2024
Journal Articles

BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results

Susan Bal, Myo Htut, Jesús G. Berdeja, Larry D Anderson, Jr., Adriana Rossi, Tara Gregory, Thomas G Martin, Luciano J. Costa, Hongxiang Hu, Jinjie Chen, Chaoqun Mei, Naomey Sarkis, Alok Shrestha, Safiyyah Ziyad, Wei-Ming Kao, Allison J Kaeding, Michael R. Burgess, Omar Nadeem
Journal: Blood
Blood (2024) 144 (Supplement 1): 2069.
https://doi.org/10.1182/blood-2024-203279
Published: 2024
Journal Articles

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Susan Bal, M. Hakan Kocoglu, Omar Nadeem, Myo Htut, Tara Gregory, Larry D. Anderson, Jr., Luciano J. Costa, Tonia J. Buchholz, Safiyyah Ziyad, Meng Li, Yanping Chen, Allison J. Kaeding, Michael R. Burgess, Kristen Hege, Jesus Berdeja
Journal: Blood
Blood (2022) 140 (Supplement 1): 883–885.
https://doi.org/10.1182/blood-2022-162395
Published: 2022
Journal Articles

Discovery and Validation of Cell-Surface Protein Mesothelin (MSLN) As a Novel Therapeutic Target in AML: Results from the COG/NCI Target AML Initiative

Katherine Tarlock, MD, Allison J. Kaeding, Todd A. Alonzo, PhD, Michael R. Loken, PhD, Rhonda E. Ries, MA, Laura Pardo, Robert Gerbing, BS, Jason E Farrar, MD, Jaime M. Guidry Auvil, PhD, Daniela S. Gerhard, PhD, Malcolm A. Smith, MD PhD, Tanja M. Davidsen, PhD, Pattee Gesuwan, Leandro C. Hermida, Marco A. Marra, PhD, Andrew J. Mungall, Karen Mungall, PhD, Yussanne Ma, PhD, Stuart Zong, William Long, PhD, Alan S. Gamis, MD MPH, E. Anders Kolb, MD, Soheil Meshinchi, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2873.
https://doi.org/10.1182/blood.V128.22.2873.2873
Published: 2016
Journal Articles

MLL Rearrangement and Age At Diagnosis Are Strongly Associated with High Level Surface FLT3 Expression and Ex Vivo Sensitivity to FLT3 Inhibition: A Prospective Analysis of 54 Consecutive Infants with ALL Enrolled in Children's Oncology Group (COG) Trial AALL0631

Allison J. Kaeding, Daniel Magoon, Yarden Fraiman, Tamekia Jones, PhD, Nyla A. Heerema, PhD, Andrew J. Carroll, PhD, Kathleen W. Rao, PhD, Joanne M. Hilden, MD, Stephen P. Hunger, MD, Donald Small, MD, PhD, Patrick A. Brown, MD
Journal: Blood
Blood (2011) 118 (21): 568.
https://doi.org/10.1182/blood.V118.21.568.568
Published: 2011